Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Finerenone (formerly known as BAY94-8862; BAY-948862; Kerendia) is a potent, selective, and orally bioavailable non-steroidal anti-mineralocorticoid or mineralocorticoid receptor (MR) antagonist (IC50 = 18 nM) that was approved in July 2021 by the US FDA to reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes. It was in phase III clinical trials for the treatment of chronic heart failure since October 2015. Finerenone has less relative affinity to other steroid hormone receptors than currently available antimineralocorticoids such as eplerenone and spironolactone, which should result in fewer adverse effects like gynaecomastia, impotence, and low sex drive.
ln Vivo |
In Munich Wistar Frömter (MWF) rats, finerenone (BAY 94-8862) dramatically lowers systolic blood pressure (SBP) and reduces proteinuria by >40% [1].
|
---|---|
Animal Protocol |
Animal/Disease Models: 12weeks old MWF rats[1]
Doses: 10 mg/kg Route of Administration: Po; one time/day for 4 weeks. Experimental Results: The systolic blood pressure of MWF rats was Dramatically diminished; resulting in significant albuminuria in the MWF model. Dramatically diminished (>40%). Animal/Disease Models: 12weeks old MWF rats[1] Doses: 10 mg/kg Route of Administration: Po; one time/day for 4 weeks. Experimental Results: The systolic blood pressure of MWF rats was Dramatically diminished; resulting in significant albuminuria in the MWF model. Dramatically diminished (>40%). |
References |
[1]. Bärfacker L, et al. Discovery of BAY 94-8862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem. 2012;7(8):1385-1403.
[2]. González-Blázquez R, et al. Finerenone Attenuates Endothelial Dysfunction and Albuminuria in a Chronic Kidney Disease Model by a Reduction in Oxidative Stress. Front Pharmacol. 2018;9:1131. Published 2018 Oct 9. |
Molecular Formula |
C21H22N4O3
|
---|---|
Molecular Weight |
378.4244
|
CAS # |
1050477-31-0
|
Related CAS # |
(Rac)-Finerenone;1050477-27-4
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O(CC)C1C2=C(C(C)=CN=1)NC(C)=C(C(N)=O)[C@@]2([H])C1C=CC(C#N)=CC=1OC
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~200 mg/mL (~528.51 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. Solubility in Formulation 2: ≥ 1.93 mg/mL (5.10 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 19.3 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.93 mg/mL (5.10 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.6426 mL | 13.2128 mL | 26.4257 mL | |
5 mM | 0.5285 mL | 2.6426 mL | 5.2851 mL | |
10 mM | 0.2643 mL | 1.3213 mL | 2.6426 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.